Commitment and collaboration

Commitment and collaboration

Commitment and collaboration

Commitment and collaboration

Commitment and collaboration

Commitment and collaboration

Commitment and collaboration

Together, we are committed to making a difference – to patients, the healthcare system and the society in which we are embedded.

Basilea at a glance

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 150 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections. In addition, we have preclinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).

Vision and mission

People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.

Sustainability

By focusing our business on the research and development of novel anti-infectives we contribute to addressing global health priorities – with expertise, care and persistence.

Please see full ESG factsheet

Materiality analysis

Our goal is to be able to operate successfully in the long term while minimizing negative effects of our activities and contributing to our mission of being a leading provider of innovative medicines for the benefit of patients.

Concept of “double materiality”

In order to comply with the expectations of our stakeholders, the requirements of EU and Swiss regulations, and the GRI standards (2021), we will publish a regularly updated materiality matrix in our annual sustainability report. In accordance with best practice, we look at each material topic from two different perspectives, using the concept of “double materiality”:

  1. The “outside-in” perspective: How relevant is a topic for our long-term (business) success?
  2. The “inside-out” perspective: What is the impact of our business activities in this area?

Process steps

By means of an online survey we collected input from our employees, representing all our business functions. The employees rated the relevance of each topic from both perspectives (outside-in and inside-out). The results of this survey were then consolidated and presented to Basilea’s management committee. To validate the materiality matrix, we held two workshops with the management committee to discuss, evaluate and agree on the final materiality matrix.

Focus topics for our ESG strategy

Our materiality analysis has identified nine topics that are of particular importance either to Basilea’s long-term success and/or to the environment in which we operate. We refer to these areas as focus topics as shown in the materiality matrix below.

These nine focus topics are:

  • Product quality and safety
  • Antimicrobial resistance
  • Animal handling
  • Compliance
  • Drug pricing and reimbursement
  • Intellectual property protection
  • Human capital development
  • Diversity, equality and inclusion
  • Economic performance

We pursue them strategically and aim to make measurable progress against them.

As part of our materiality analysis, we have also identified topics that we wish to monitor and, in some cases, actively manage. In the interest of full transparency, we will also disclose these topics in future sustainability reporting.

 

 

Basilea’s materiality matrix 2023

Basilea's Materiality Matrix August 2023

Organization

Board of directors

 

Board committees

Audit committee Compensation committee Corporate governance & nomination committee
Leonard Kruimer
(Chairman)
Dr. Martin Nicklasson
(Chairman)
Dr. Thomas Werner
(Chairman)
Dr. Martin Nicklasson Dr. Nicole Onetto Dr. Carole Sable
Domenico Scala Dr. Thomas Werner Domenico Scala

For further information on the responsibilities of the board committees, please refer to the latest annual report.

Management committee

 

Extended management committee